Skip to main content

Skip to main navigation

The Economic Case for Universal Pharmacare

Costs and benefits of publicly funded drug coverage for all Canadians

About this Publication

The main argument that is typically made against the establishment of universal Pharmacare is economic in nature. This report shows that the economic argument in favour of such a program is loud and clear, regardless of which industrial policy is subsequently considered. Canadians could save between 10% and 42%—up to $10.7 billion—of total drug expenditures.

A universal drug plan providing first-dollar coverage, established alongside a rigorous drug assessment process, would not only ensure greater fairness in accessing medication and improve drug safety, but would also help contain the inflationary costs of drugs, regardless of the industrial policy Canada may choose.

Find Publications

Support Our Work

Over the last 30 years, the CCPA has provided alternative research and analysis that have been indispensable in exposing the corporate agenda. I don’t know what I’d have done without them.

— Judy Rebick

Join or Donate

Email Newswire

Stay up to date on new research:
About our newswire service
CCPA National Office | Suite 205, 75 Albert Street, Ottawa, ON, K1P 5E7 | Tel: 613-563-1341 | Fax: 613-233-1458 | E-mail: ccpa@policyalternatives.ca
© 2012 Canadian Centre for Policy Alternatives | research • analysis • solutions | Want to use something on this site? View our terms of re(use)
Website Design & Development by Raised Eyebrow Web Studio